Sanofi snaps up Vicebio to boost its vaccine toolbox
In a move that could set the stage for a new era in respiratory defense, Sanofi has added London‑based Vicebio to its roster. This isn’t just a quick tidy‑up; it’s a deliberate strategy to widen its reach beyond the popular mRNA realm.
Vicebio’s specialties? Think less about the headline‑making spike‑protein tech and more about solid, time‑tested approaches. Sanofi’s CEO hinted this would give the French giant an extra weapon in its arsenal—something that works outside the mRNA bubble and could help keep the world a step ahead of future lung‑invasive threats.
- Expanding horizons: The acquisition unlocks new vaccine options that target respiratory viruses beside the current mRNA lineup.
- Fresh perspective: Vicebio’s knowledge of non‑mRNA platforms brings fresh tactics to Sanofi’s research pipeline.
- Global impact: This move could strengthen stockpiles for global health emergencies and provide a broader spectrum of protective options.
With this deal, Sanofi not only widens its portfolio but also signals confidence in diverse vaccine technologies— proving that the future of disease prevention isn’t one‑size‑fits‑all.
Sanofi’s Bold Bite: Buying Vicebio to Fight Respiratory Bugs
In a move that feels a bit like a foodie merger, Sanofi has decided to snap up London‑based biotech Vicebio. They’re offering a sweet $1.15 billion upfront (about €980 million) and could add up to $450 million more once the new vaccine hits the finish line.
“We’re on board!” – Vicebio’s CEO faces the future
“We’re thrilled to join Sanofi,” said Emmanuel Hanon, Vicebio’s CEO. “Their global reach and powerhouse experience in vaccine science gives our tech the perfect playground to shine.”
What Sanofi Gains
- Vicebio’s early‑stage combo vaccine for RSV (respiratory syncytial virus) and hMPV (human metapneumovirus)
- A non‑mRNA punch in the vaccine lineup – no novel mRNA tricks, just solid science that’s been out in the wild for a while.
- The cutting‑edge Molecular Clamp tech, which locks viral proteins in their natural shape, letting the immune system hit them harder and faster.
Why This Matters
Respiratory illnesses are the common “cold” that can sometimes turn into a full‑blown pneumonia nightmare. By grabbing Vicebio, Sanofi turns the tables: they now have a promise‑packed combo that could arm seniors with a single shot against multiple nasties.
What the Future Looks Like
Expect the deal to close out of 2025. The financial forecast remains smooth sailing, and the stock’s just a touch down 0.4% right before 11:00 CEST in Paris.
